Findings

What do systematic reviews say?

145 questions · 145 findings · 20 reviews · Hypertension

Sort:Best matchNewest Highest certainty Download CSV

No studies found 20 · 13.8%GRADE not reported 4 · 2.8%Very low 19 · 13.1%Low 32 · 22.1%Moderate 23 · 15.9%High 47 · 32.4%

Intervention not reported

Triglycerides fluvastatin 40 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
48 studies · 2646 participants
High

Intervention not reported

Triglycerides fluvastatin 80 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 3623 participants
High

Intervention not reported

CI: Confidence interval · participants with normal or abnormal lipid profiles

The review found no eligible studies for this question.

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Mean baseline values. · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Intervention not reported

WDAEs within 3‐12 weeks · participants with normal or abnormal lipid profiles

It is very uncertain whether the intervention changes WDAEs within 3‐12 weeks (very low certainty).

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
RR 1.52 [0.94, 2.45]
16 studies · 3023 participants
Very low

Intervention not reported

LDL‐cholesterol fluvastatin 20 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
55 studies · 9010 participants
High

Intervention not reported

LDL‐cholesterol fluvastatin 40 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
57 studies · 3658 participants
High

Intervention not reported

LDL‐cholesterol fluvastatin 80 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
32 studies · 4928 participants
High

Intervention not reported

CI: Confidence interval · participants with normal or abnormal lipid profiles

The review found no eligible studies for this question.

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Mean baseline values. · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Intervention not reported

Total cholesterol fluvastatin 10 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 287 participants
High

Intervention not reported

Total cholesterol fluvastatin 20 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
50 studies · 6309 participants
High

Intervention not reported

Total cholesterol fluvastatin 40 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
55 studies · 2966 participants
High

Intervention not reported

Systolic BP ‐ Aliskiren 75 mg vs. placebo · primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1100 participants
Moderate

Intervention not reported

Systolic BP ‐ Aliskiren 150 mg vs. placebo · primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 3786 participants
Moderate

Intervention not reported

Systolic BP ‐ Aliskiren 300 mg vs. placebo · primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 3009 participants
Moderate

Intervention not reported

Systolic BP ‐ Aliskiren 600 mg vs. placebo · primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 393 participants
Low

Intervention not reported

Diastolic BP ‐ Aliskiren 75 mg vs placebo · primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1100 participants
Moderate

Intervention not reported

Diastolic BP ‐ Aliskiren 150 mg vs placebo · primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 3783 participants
Moderate

Intervention not reported

Diastolic BP ‐ Aliskiren 300 mg vs placebo · primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 3001 participants
Moderate